Phoenix, AZ (November 12, 2025) – Tucson-based SynCardia Systems, LLC, the manufacturer of the SynCardia Total Artificial Heart, is a wholly owned subsidiary of Picard Medical, Inc. Picard Medical became a publicly traded company on August 29, 2025, and completed its Initial Public Offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross proceeds.
Shares of Picard Medical trade on the NYSE American under the ticker symbol PMI. Through SynCardia, the company develops and manufactures the SynCardia Total Artificial Heart — the only commercially available total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
SynCardia continues its mission to save lives through groundbreaking artificial heart technology, launching new initiatives to expand awareness, advance product innovation, and highlight inspiring patient stories.
Despite more than 2,100 SynCardia Total Artificial Heart implants to date, many hospitals remain unaware of its life-saving potential.
“Raising visibility is critical to help more patients who might not survive waiting for a transplant,” said Britt Lanza, Marketing Manager at SynCardia.
As the only FDA and Health Canada-approved total artificial heart, SynCardia is strengthening partnerships with the Phoenix Bioscience Core (PBC) and Venture Café to boost visibility and community engagement.
SynCardia’s total artificial heart allows patients to live active, independent lives while awaiting a transplant. Available in two sizes — 70cc and 50cc — the system uses the same proven mechanism across all patients. The Freedom portable driver, weighing just under 13 pounds, enables mobility and freedom, with patients remaining active until a donor heart is located. The SynCardia Total Artificial Heart stands as the benchmark for clinical performance, durability, and patient outcomes.
Looking ahead, the upcoming Emperor model, a fully implantable version of the SynCardia Total Artificial Heart, aims to eliminate the need for external devices and further enhance patients’ quality of life.
“Our long-term vision is a world where the Emperor is a true alternative to heart transplantation,” Lanza shared.
This next-generation device reinforces SynCardia’s mission to reduce patient burden and expand access to life-saving technology worldwide.
As part of its outreach strategy, SynCardia is also spotlighting patient experiences to humanize its technology and demonstrate its real-world impact. In collaboration with Unique Beating Hearts (UBH), upcoming articles and campaigns will feature authentic patient stories, building stronger emotional connections and public awareness.
To boost awareness and optimize outreach, SynCardia is broadening its event strategy to incorporate high-value regional opportunities such as Venture Café and Arizona Tech Week. “We’re refining our approach to better measure ROI and maximize impact,” said Lanza, noting that incorporating high-value regional events will further strengthen the company’s presence and outreach efforts.
About the Phoenix Bioscience Core
The Phoenix Bioscience Core (PBC) is a 30-acre life sciences innovation district located in downtown Phoenix. It hosts Arizona’s three public research universities—Arizona State University, Northern Arizona University, and the University of Arizona—as well as leading genomics pioneers like the Translational Genomics Research Institute (TGen), part of the City of Hope, and the International Genomics Consortium. The PBC also collaborates with major healthcare systems, including Banner Health, Phoenix Children’s Hospital, Dignity Health, HonorHealth, Phoenix VA, and Valleywise Health, alongside a growing number of emerging life science companies. This unique concentration of research scientists and healthcare professionals fosters unprecedented collaborations, advancing precision medicine from discovery to delivery. To learn more, please visit phoenixbiosciencecore.com.
About SynCardia
SynCardia Systems, LLC (“SynCardia”) is a wholly owned subsidiary of Picard Medical, Inc., the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
By: Madisson Simental | November 12, 2025